Takeda Agrees To Buy Shire In £46bn Deal

Adjust Comment Print

Hattrell also represented Shire on its $5.2bn acquisition of U.S. company NPS Pharmaceuticals in 2015 and when it was the subject of an attempted takeover by USA drugmaker AbbVie in 2014.

Shire shareholders will own 50% of the enlarged group following the deal, which is expected to complete in the first half of 2019.

Under the terms of the deal, Shire investors will receive $30.33 in cash for each share they own, plus shares in Takeda, making the total offer worth about £49 a share.

Shire's shares climbed more than three per cent in early trading.

For the deal between Takeda and Shire to proceed, 75% of Shire's voting shareholders must support the transaction.

Based on regulations in Britain's stock exchange, where Shire is now listed, the two drugmakers have extended the deadline for announcing whether they will formally propose the acquisition from 5 p.m. on April 25 to 5 p.m. on Tuesday London time.

Atty. Gen. Sessions Vows to Prosecute All Who Illegally Cross Border
Sessions' visit follows a March visit by President Donald Trump to Otay Mesa to survey border wall prototypes. If you are smuggling a child, we will prosecute you.

Ronaldo to undergo tests on his ankle injury, confirms Zidane
Ramos said the dispute continued down the tunnel, with Messi at the centre of the complaining. He controls the ball and then I put his foot out of place.

Madrid never give up: Zidane
They should thank (goalkeeper Keylor) Navas for his performance, especially toward the end of the match". But it was a lot better in the second half.

Takeda, founded in Osaka in 1781, wants Shire, a specialist in the treatment of rare conditions, to help it expand globally - especially in the United States - as it faces down the prospect of weaker drug prices in its home market. Previous year it bought Ariad Pharmaceuticals of Cambridge, Massachusetts.

Takeda said $30.1 billion in bridge loan financing would be replaced with a combination of long-term debt, hybrid capital and available cash ahead of completion, without providing a breakdown.

The companies eventually expect to realize about $1.4 billion in annual cost savings from combining, the majority of which will come from reducing duplicative functions in sales and marketing, Takeda said.

Takeda had previously said that expanding its oncology business was a significant reason why it was considering a bid for Shire, along with the desire to expand in along with gastrointestinal medicine and neuroscience.

The two companies now have more than 50,000 employees between them worldwide and more than 5,000 in MA, making it potentially the biggest pharmaceutical employer in the state.

Takeda said it would maintain its global headquarters in Japan and evaluate consolidating Shire's operations into Takeda's in the Boston area, Switzerland and Singapore. And it intends to keep its investment-grade credit rating, targeting a debt-to-EBITDA ratio of 2x or less in a few years. A quarter of Shire's product revenues a year ago came from sales of its hemophilia medicines, which face competition from Roche's Hemlibra (emicizumab) now and potentially curative gene therapies in the future.